George Daniel J, Regan Meredith M, Oh William K, Tay Miah-Hiang, Manola Judith, Decalo Niv, Duggan Stephen, Dewolf William C, Kantoff Philip W, Bubley Glenn J
Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Urology. 2004 Feb;63(2):327-32. doi: 10.1016/j.urology.2003.09.059.
To measure the change in plasma vascular endothelial growth factor (VEGF) levels after radical prostatectomy (RP) and to examine the association of pre-RP VEGF levels with known prognostic factors.
Plasma was collected from patients in two separate cohorts. The first cohort included 86 patients who consented to give blood before and after RP. The second cohort consisted of 280 plasma samples, obtained from untreated patients with clinically localized prostate cancer. Plasma VEGF levels were measured by enzyme-linked immunosorbent assay. The change in plasma VEGF before and 6 to 8 weeks after RP was analyzed using a Wilcoxon signed rank test. The associations between the pre-RP VEGF levels and prognostic factors were assessed with the Spearman correlation coefficient and the Kruskal-Wallis test.
In a cohort of 86 patients with clinically localized prostate cancer, the median preoperative VEGF level was 49.8 pg/mL. The median level 1 month after surgery was significantly lower at 39.1 pg/mL (P = 0.006, 20% decrease). A repeat analysis 6 months or more after surgery demonstrated that the percentage of decrease in the plasma VEGF levels persisted. Plasma VEGF levels were also measured in a separate cohort of 280 patients with localized prostate cancer and demonstrated no statistically significant association with risk groups or known tumor-associated prognostic factors.
These results suggest that the prostate gland itself may be a significant source of systemic VEGF and raises the possibility that elevated plasma VEGF levels could be a reflection of prostatic VEGF production.
测量根治性前列腺切除术后(RP)血浆血管内皮生长因子(VEGF)水平的变化,并检查RP术前VEGF水平与已知预后因素的相关性。
从两个独立队列的患者中采集血浆。第一个队列包括86名同意在RP前后献血的患者。第二个队列由280份血浆样本组成,这些样本来自未经治疗的临床局限性前列腺癌患者。采用酶联免疫吸附测定法测量血浆VEGF水平。使用Wilcoxon符号秩检验分析RP术前和术后6至8周血浆VEGF的变化。用Spearman相关系数和Kruskal-Wallis检验评估RP术前VEGF水平与预后因素之间的相关性。
在一组86例临床局限性前列腺癌患者中,术前VEGF水平中位数为49.8 pg/mL。术后1个月时中位数水平显著降低,为39.1 pg/mL(P = 0.006,下降20%)。术后6个月或更长时间的重复分析表明,血浆VEGF水平的下降百分比持续存在。在另一组280例局限性前列腺癌患者中也测量了血浆VEGF水平,结果显示与风险组或已知的肿瘤相关预后因素无统计学显著相关性。
这些结果表明前列腺本身可能是全身VEGF的重要来源,并增加了血浆VEGF水平升高可能反映前列腺VEGF产生的可能性。